Why Your Sleep Lab Is Probably ResMed-Only (And Why That's a Problem)

You Think You Need 'The Quietest' Machine. But That's Not the Real Issue.

If you've ever stood in a supply closet overflowing with AirSense 11 boxes and thought, "Wait—do we even have enough filters for all these?", you already know the pain. As a Quality & Brand Compliance manager for a medical device distributor, I review specs on roughly 200+ unique SKUs a year. And I've rejected about 7% of first deliveries in 2024—mostly because of stuff like incompatible masks or missing accessories.

Here's the thing most sleep lab managers won't say out loud: going all-in on ResMed looks like a safe bet until it isn't.

Let me explain why standardizing on a single brand—even one as dominant as ResMed—can quietly wreck your inventory, your budget, and your patients' compliance rates. And no, this isn't a pitch for Philips or Fisher & Paykel. I'm not here to dump on competitors.

The Surface Problem: "ResMed Seems Like the Obvious Choice"

You know the pitch. ResMed owns something like 60-70% of the global CPAP market. Their devices are clinically validated. Their apps (myAir) are the most polished in the space. Every sleep physician has seen an AirCurve 10 manual at least once. And their AirSense 11 air filter is stupidly easy to swap—it practically tells you when it's dirty.

When I ran a blind test with our device evaluation team—same mask interface, same pressure settings, but a ResMed AirCurve 10 vs. a comparable device from Fisher & Paykel—68% of testers picked the ResMed as 'more polished' without knowing what they were using. On a 50,000-unit annual order, that kind of perception matters. It cost us about $18,000 more per shipment to go with ResMed, but the compliance rates were 8% higher in the first two weeks.

So yeah—ResMed earns its reputation. But here's something most vendors won't tell you: that comfort can trap you.

"What most people don't realize is that 'standard' ResMed procurement often includes buffer stock for emergencies—but that buffer is calculated assuming perfect supply chain. It isn't."

The Deep Reason: You Optimized for Comfort, Not Resilience

Every spreadsheet analysis I've seen from purchasing teams points to the same conclusion: ResMed offers the best user experience per dollar. That's true for about 80% of use cases.

The problem is that the remaining 20%—the edge cases—are where most of your headaches live. Here are three that my team documented in our Q1 2024 audit:

• Mask ecosystem lock-in: ResMed's new mask connectors are proprietary. If a patient's preferred full face frame is a ResMed model, you can't swap in a Fisher & Paykel cushion without an adapter. That's by design—but it means your inventory is tied to one supplier's availability.
• Software dependency: myAir is great—until their cloud service goes down. In August 2023, a 12-hour outage left our remote monitoring team unable to adjust pressures for 340 patients. We had to revert to manual phone calls. Cost us 22 hours of overtime.
• Firmware quirks: The AirSense 11's algorithm for 'auto-ramp' works slightly differently than the AirCurve 10's. If you're mixing both in a fleet, your titration protocols get inconsistent. That quality issue cost us a $22,000 redo and delayed our launch by three weeks.

The Cost of Ignoring This: More Than Just Money

In 2022, our company signed an exclusive contract with ResMed for a 3-year fleet replacement. We thought we were saving 14% on bulk pricing. What we didn't anticipate:

• Supply chain shocks: When ResMed faced a chip shortage in Q3 2022, our filter shipments were delayed 6 weeks. We ran out of AirSense 11 air filters for 11 days. A competitive lab across town had stockpiled universal alternatives.
• Compliance gaps: Exclusive fleets mean patients can't bring in their own masks. If a patient loves a non-ResMed nasal pillow, you're out of luck. That patient's adherence dropped 23% in the first month.
• Bidding power erosion: Once you're locked in, procurement leverage disappears. Renewals become 'take it or leave it' pricing. I've seen labs pay 18% more for the same device in year 2 of a 3-year contract.

If this sounds familiar, you're not alone. In a 2023 survey of 40 sleep labs (that I participated in), 63% said they felt 'overly dependent' on a single CPAP vendor—but only 21% had a formal multi-vendor strategy.

The Honest Fix: Stop Choosing a Winner. Start Managing a Fleet.

I'm not recommending you dump ResMed. That would be stupid. Their devices are excellent, their support is decent, and their brand is strong. But here's where I draw the line: if your entire procurement strategy is 'we buy ResMed,' you're not practicing medicine—you're practicing brand loyalty.

Here's what I'd do instead, based on what we implemented after that Q3 2022 filter fiasco:

• 80/20 rule: Keep ResMed as your primary fleet (80% of devices). But allocate 20% to a second vendor (Fisher & Paykel or Lowenstein) as a backup supply. This gives you leverage and a safety net.
• Cross-train your staff: Every respiratory therapist on your team should be comfortable with at least two brands. It's not hard—we did a 2-hour workshop and saw device setup errors drop 40%.
• Audit your inventory monthly: I run a blind 'stockout drill' with my team: simulate a 4-week delay from ResMed. If you can't cover your patients, you have a resilience problem.

Does this add complexity? Yes. Will it cost a bit more upfront? Probably—maybe 5-10% more in year one for dual-vendor training and adapter stock. But when the next chip shortage hits, you'll be glad you did.

Take it from someone who watched 8,000 units sit in a warehouse because the filters didn't arrive: brand loyalty is a cost, not a benefit. Know when to stick with the leader—and when you need a plan B.

Pricing as of January 2025. Verify current rates with ResMed directly. And no, I don't work for them. I just audit their stuff.